Characterization of the human cytochrome P450 forms involved in metabolism of tamoxifen to its α-hydroxy and α,4-dihydroxy derivatives

Chemical Research in Toxicology

Volumn 18, Issue 10, 2005, Pages 1611-1618

  Notley, L M ^a   Crewe, K H ^b   Taylor, P J ^a   Lennard, M S ^b   Gillam, E M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ALPHA HYDROXYNORTAMOXIFEN; ALPHA HYDROXYTAMOXIFEN; ALPHA,4 DIHYDROXYTAMOXIFEN; CARCINOGEN; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; HYDROXYTAMOXIFEN; NORTAMOXIFEN; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INCIDENCE; CONCENTRATION RESPONSE; DRUG ACTIVATION; DRUG DNA BINDING; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSFORMATION; ENDOMETRIUM CANCER; ENZYME SUBSTRATE COMPLEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN;

ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RECOMBINANT PROTEINS; TAMOXIFEN;

EID: 27144459972     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050140s     Document Type: Article

References (51)

1. Fisher, B., Constantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer. Inst. 90, 1371-1388.
2. IARC (1996) Some pharmaceutical drugs. IARC Monogr. 66, 253.
3. Hardcastle, I. R., Horton, M. N., Osborne, M. R., Hewer, A., Jarman, M., and Phillips, D. H. (1998) Synthesis and DNA reactivity of α-hydroxylated metabolites of nonsteroidal antiestrogens. Chem. Res. Toxicol. 11, 369-374.
4. Phillips, D. H., Hewer, A., Horton, M. N., Cole, K. J., Carmichael, P. L., Davis, W., and Osborne M. R. (1999) N-Demethylation accompanies α-hydroxylation in the metabolic activation of tamoxifen in rat liver cells. Carcinogenesis 20, 2003-2009.
5. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., and Poon, G. K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54, 5518-5522.
6. Phillips, D. H., Potter, G. A., Horton, M. N., Hewer, A., Crofton-Sleigh, C., Jarman, M., and Venitt, S. (1994) Reduced genotoxicity of [D5-ethyl]tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver cacinogen. Carcinogenesis 15, 1487-1492.
7. Davis, W., Venitt, S., and Phillips, D. H. (1998) The metabolic activation of tamoxifen and α-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 19, 861-866.
8. Dasaradhi, L., and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 10, 189-196.
9. Poon, G. K., Walter, B., Lonning, P. E., Horton, M. N., and McCague, R. (1995) Identification of tamoxifen metabolites in human HepG2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23, 377-382
10. Boocock, D. J., Maggs, J. L., White, I. N. H., and Park, B. K. (1999) α-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: Identification and quantification in vivo and in vitro. Carcinogenesis 20, 153-160.
11. Shibutani, S., and Dasaradhi, L. (1997) Miscoding potential of tamoxifen-derived DNA adducts: α-(N2-Deoxyguanosinyl)tamoxifen. Biochemistry 36, 13010-13017.
12. Terashima, I., Suzuki, N., and Shibutani, S. (1999) Mutagenic potential of α-(N2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 59, 2091-2095.
13. Shibutani, S., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12, 646-653.
14. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 10, 189-196.
15. Martin, E. A., Brown, K., Gaskell, M., Al-Azzawi, F., Garner, R. C., Boocock, D. J., Mattock, E., Pring, D. W., Dingley, K., Turteltaub, K. W., Smith, L. L., and White, I. N. H. (2003) Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry. Cancer Res. 63, 8461-8465.
16. Randerath, K., Moorthy, B., Mabon, N., and Sriram, P. (1994) Tamoxifen: Evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087-2094.
17. Osborne, M. R., Davis, W., Hewer, A. J., Hardcastle, I. R., and Phillips, D. H. (1999) 4-Hydroxytamoxifen gives DNA adducts by chemical activation, but not in rat liver cells. Chem. Res. Toxicol. 12, 151-158.
18. Beland, F. A., McDaniel, L. P., and Marques, M. M. (1999) Comparison of adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 20, 471-477.
19. Marques, M. M., and Beland, F. A. (1997) Identification of tamoxifen-DNA adducts formed by 4-hydroxytamoxifen quinone methide. Carcinogenesis 18, 1949-1954.
20. Fan, P. W., Zhang, F., and Bolton, J. L. (2000) 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem. Res. Toxicol. 13, 45-52.
21. McLuckie, K. I. E., Routledge, M. N., Brown, K., Gaskell, M., Farmer, P. B., Roberts, G. C. K., and Martin, E. A. (2002) DNA adducts formed from 4-Hydroxytamoxifen are more mutagenic than those formed by α- acetoxytamoxifen in a shuttle vector target gene replicated in human Ad293 cells. Biochemistry 41, 8899-8906.
22. Brown, K., Heydon, R. T., Jukes, R., White, I. N. H., and Martin, E. A. (1999) Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N,N-didesmethyltamoxifen. Carcinogenesis 20, 2011-2016.
23. Kitagawa, M., Ravindernath, A., Suzuki, N., Rieger, R., Terashima, I., Umemoto, A., and Shibutani, S. (2000) Identification of tamoxifen-DNA adducts induced by α-acetoxy-N-desmethyltamoxifen. Chem. Res. Toxicol. 13, 761-769.
24. Crewe, H. K., Ellis, S. W., Lennard, M. S., and Tucker, G. T. (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171-178.
25. Dehal, S. S., and Kupfer, D. (1997) CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 57, 3402-3406.
26. Dehal, S. S., and Kupfer, D. (1999) Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 27, 681-688.
27. Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., and Gillam, E. M. J. (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: Formation of the 4-hydroxy, 4′-hydroxy and N-demethyl metabolites and isomerization of irans-4-hydroxytamoxifen. Drug Metab. Dispos. 30, 869-874.
28. Kim, S. Y., Suzuki, N., Laxmi, Y. R. S., Rieger, R., and Shibutani, S. (2003) α-Hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Chem. Res. Toxicol. 16, 1138-1144.
29. Desta, Z., Ward, B. A., Soukhova, N. V., and Flockhart, D. A. (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 210, 1062-1075.
30. Boocock, D. J., Maggs, J. L., Brown, K., White, I. N. H., and Park, B. K. (2000) Major inter-species differences in the rates of O-sulphonation and O-glucuronidation of α-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 21, 1851-1858.
31. Sharma, M., Shubert, D. E., Sharma, M., Lewis, J., McGarrigle, B. P., Bofmger, D. P., and Olson, J. R. (2003) Biotransformation of tamoxifen in a human endometrial explant culture model. Chem.-Biol. Interact. 146, 237-249.
32. Guengerich, F. P. (1994) Analysis and characterization of enzymes. In Principles and Methods of Toxicology, 3rd ed. (Hayes, A. W., Ed.) pp 1259-1313, Raven Press Ltd., New York.
33. Parikh, A., Gillam, E. M. J., and Guengerich, F. P. (1997) Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotechnol. 15, 784-788.
34. Gillam, E. M. J., Ueng, Y.-F., Wunsch, R. M., Shimada, T., Kamataki, T., and Guengerich, F. P. (1997) Expression of cytochrome P450 3A7 in Escherichia coli: Effects of 5′ modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 346, 81-90.
35. Shimada, T., Wunsch, R. M., Hanna, I. H., Sutter, T. R., Guengerich, F. P., and Gillam, E. M. J. (1998) Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch. Biochem. Biophys. 357, 111-120.
36. Cuttle, L., Munns, A. J., Hogg, N. A., Scott, J. R., Hooper, W. D., Dickinson, R. G., and Gillam, E. M. J. (2000) Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab. Dispos. 28, 945-950.
37. Shimada, T., Watanabe, J., Kawajiri, K., Sutter, T. R., Guengerich, F. P., Gillam, E. M. J., and Inoue, K. (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607-1613.
38. Gillam, E. M. J., Guo, Z., Martin, M. V., Jenkins, C. M., and Guengerich, F. P. (1995) Expression of cytochrome P450 2D6 in Escherichia coli, purification, and spectral and catalytic characterization. Arch. Biochem. Biophys. 319, 540-550.
39. Gillam, E. M. J., Baba, T., Kim, B.-R., Ohmori, S., and Guengerich, F. P. (1993) Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123-131.
40. Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H., and Yura, T. (1998) Chaperone coexpression plasmids: Differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese Cedar pollen, Cryj2, in Escherichia coli. Appl. Environ. Microbiol. 64, 1694-1699.
41. Inoue, H., Nojima, H., and Okayama, H. (1990) High efficiency transformation of Escherichia coli with plasmids. Gene 96, 23-28.
42. Hukkanen, J., Mantyla, M., Kangas, L., Wirta, P., Hakkola, J., Paakki, P., Evisalmi, S., Pelkonen, O., and Raunio, H. (1998) Expression of cytochrome P450 genes encoding enzymes active in the metabolism of tamoxifen in human uterine endometrium. Pharmacol. Toxicol. 82, 93-97.
43. Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., and Skaar, T. C. (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159.
44. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E., and Duffel, M. W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58, 647-653.
45. Shibutani, S., Shaw, P. M., Suzuki, N., Dasaradhi, L., Duffel, M. W., and Terashima, I. (1998) Sulfation of α-hydroxytamoxifen catalysed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 19, 2007-2011.
46. Shibutani, S., Reardon, J. T., Suzuki, N., and Sancar, A. (2000) Excision of tamoxifen-DNA adducts by the human nucleotide excision repair system. Cancer Res. 60, 2607-2610.
47. Shimada, T., Tsumura, F., Gillam, E. M. J., Guengerich, F. P., and Inoue, K. (2000) Roles of NADPH-P450 reductase in the O-deethylation of 7-ethoxycoumarin by recombinant human cytochrome P450 IBl variants in Escherichia coli. Protein Expression Purif. 20, 73-80.
48. Rajaniemi, H., Rasanen, I., Koivisto, P., Peltonen, K., and Hemminki, K. (1999) Identification of the major tamoxifen-DNA adducts in rat liver by mass spectroscopy. Carcinogenesis 20, 305-309.
49. MacCallum, J., Cummings, J., Dixon, J. M., and Miller, W. R. (2000) Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br. J. Cancer 82, 1629-1635.
50. Stearns, V., Johnson, M. D., Rae, J. M., Morocho, A., Novielli, A., Bhargava, P., Hayes, D. F., Desta, Z., and Flockhart, D. A. (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer. Inst. 95, 1758-1764.
51. Vadlamuri, S. V., Glover, D. D., Turner, T., and Sarkar, M. A. (1998) Regiospecific expression of cytochrome P4501A1 and 1B1 in human uterine tissue. Cancer Lett. 122, 143-150.